Keep in mind the potential ramification of a negative BARDA response PR. The validity of Generex's vaccine platform will be in question and the share price would very well be significantly depressed. The market won't care about anything else for a while. Shoot first ask questions later.

Of course a positive response from BARDA would likely result in an incredibly elevated PPS.

Double edged sword situation. Be careful what you ask for.